nach oben

Endocrine

Erschienen in:

16.06.2023 | Review

Potential impacts of SARS-CoV-2 on parathyroid: current advances and trends

verfasst von: Avaniyapuram Kannan Murugan, Ali S. Alzahrani

Erschienen in: Endocrine | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection affects several important organs including endocrine glands. Experimental studies demonstrated that the virus exploits the ACE2, a transmembrane glycoprotein on the cell surface as a receptor for cellular entry. This entry process is exclusively facilitated by other intracellular protein molecules such as TMPRSS2, furin, NRP1, and NRP2. Recent findings documented the involvement of the SARS-CoV-2 in inducing various parathyroid disorders including hypoparathyroidism and hypocalcemia, which received significant attention. This review extensively describes rapidly evolving knowledge on the potential part of SARS-CoV-2 in emerging various parathyroid disorders due to SARS-CoV-2 infection particularly parathyroid malfunction in COVID-19 cases, and post-COVID-19 conditions. Further, it presents the expression level of various molecules such as ACE2, TMPRSS2, furin, NRP1, and NRP2 in the parathyroid cells that facilitate the SARS-CoV-2 entry into the cell, and discusses the possible mechanism of parathyroid gland infection. Besides, it explores parathyroid malfunction in COVID-19 vaccine-administered cases. It also explains the possible long-COVID-19 effect on parathyroid and post-COVID-19 management of parathyroid. A complete understanding of the mechanisms of SARS-CoV-2-triggered pathogenesis in parathyroid dysfunctions may curtail treatment options and aid in the management of SARS-CoV-2-infected cases.

E. Fan, J.R. Beitler, L. Brochard, C.S. Calfee, N.D. Ferguson, A.S. Slutsky et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted. ? Lancet Respir Med 8(8), 816–821 (2020). https://doi.org/10.1016/S2213-2600(20)30304-0

COVID-19 data portal, The World Health Organizations. https://covid19.who.int/. Last accessed on May 17, 2023

Y. Asai, H. Nomoto, K. Hayakawa, N. Matsunaga, S. Tsuzuki, M. Terada et al. Comorbidities as Risk Factors for Severe Disease in Hospitalized Elderly COVID-19 Patients by Different Age-Groups in Japan. Gerontology 68(9), 1027–1037 (2022). https://doi.org/10.1159/000521000CrossRefPubMed

M.Y. Li, L. Li, Y. Zhang, X.S. Wang, Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty 9, 45 (2020). https://doi.org/10.1186/s40249-020-00662-xCrossRefPubMedPubMedCentral

G. Lisco, A. De Tullio, A. Stragapede, A.G. Solimando, F. Albanese, M. Capobianco et al. COVID-19 and the Endocrine System: A Comprehensive Review on the Theme. J. Clin. Med 10(13), 2920 (2021). https://doi.org/10.3390/jcm10132920CrossRefPubMedPubMedCentral

G. Lisco, A. De Tullio, E. Jirillo, V.A. Giagulli, G. De Pergola, E. Guastamacchia et al. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. J. Endocrinol. Investig. 44(9), 1801–1814 (2021). https://doi.org/10.1007/s40618-021-01554-zCrossRef

G. Lisco, V.A. Giagulli, G. De Pergola, A. De Tullio, E. Guastamacchia, V. Triggiani, Covid-19 in Man: A Very Dangerous Affair. Endocr. Metab. Immune Disord. Drug Targets 21(9), 1544–1554 (2021). https://doi.org/10.2174/1871530321666210101123801CrossRefPubMed

V.A. Giagulli, E. Guastamacchia, T. Magrone, E. Jirillo, G. Lisco, G. De Pergola et al. Worse progression of COVID-19 in men: Is testosterone a key factor? Andrology 9(1), 53–64 (2021). https://doi.org/10.1111/andr.12836CrossRefPubMed

T. Fiolet, Y. Kherabi, C.J. MacDonald, J. Ghosn, N. Peiffer-Smadja, Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol Infect. 28(2), 202–221 (2022). https://doi.org/10.1016/j.cmi.2021.10.005CrossRefPubMed

10.

S.A. Clarke, A. Abbara, W.S. Dhillo, Impact of COVID-19 on the Endocrine System: A Mini-review. Endocrinology 163(1), bqab203 (2022). https://doi.org/10.1210/endocr/bqab203CrossRefPubMed

11.

M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181(2), 271–280.e8 (2020). https://doi.org/10.1016/j.cell.2020.02.052CrossRefPubMedPubMedCentral

12.

L. Cantuti-Castelvetri, R. Ojha, L.D. Pedro, M. Djannatian, J. Franz, S. Kuivanen et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370(6518), 856–860 (2020). https://doi.org/10.1126/science.abd2985CrossRefPubMedPubMedCentral

13.

B.A. Johnson, X. Xie, A.L. Bailey, B. Kalveram, K.G. Lokugamage, A. Muruato et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 591, 293–299 (2021). https://doi.org/10.1038/s41586-021-03237-4CrossRefPubMedPubMedCentral

14.

T.P. Peacock, D.H. Goldhill, J. Zhou, L. Baillon, R. Frise, O.C. Swann et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol 6, 899–909 (2021). https://doi.org/10.1038/s41564-021-00908-wCrossRefPubMed

15.

D. Wrapp, N. Wang, K.S. Corbett, J.A. Goldsmith, C.L. Hsieh, O. Abiona et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483), 1260–1263 (2020). https://doi.org/10.1126/science.abb2507CrossRefPubMedPubMedCentral

16.

S.M. Gobeil, K. Janowska, S. McDowell, K. Mansouri, R. Parks, K. Manne et al. D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. Cell Rep. 34(2), 108630 (2021). https://doi.org/10.1016/j.celrep.2020.108630CrossRefPubMed

17.

A.C. Walls, Y.J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Veesler, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181(2), 281–292.e6 (2020). https://doi.org/10.1016/j.cell.2020.02.058CrossRefPubMedPubMedCentral

18.

R. Yan, Y. Zhang, Y. Li, L. Xia, Y. Guo, Q. Zhou, Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367(6485), 1444–1448 (2020). https://doi.org/10.1126/science.abb2762CrossRefPubMedPubMedCentral

19.

C.B. Jackson, M. Farzan, B. Chen, H. Choe, Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3–20 (2022). https://doi.org/10.1038/s41580-021-00418-xCrossRefPubMed

20.

The Human Protein Atlas: https://www.proteinatlas.org. Last accessed on May 17, 2023

21.

L. He, Y. Ding, Q. Zhang, X. Che, Y. He, H. Shen et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 210(3), 288–297 (2006). https://doi.org/10.1002/path.2067CrossRefPubMedPubMedCentral

22.

S. Elkattawy, R. Alyacoub, S. Ayad, M. Pandya, A. Eckman, A Novel Case of Hypoparathyroidism Secondary to SARS-CoV-2 Infection. Cureus 12(8), e10097 (2020). https://doi.org/10.7759/cureus.10097CrossRefPubMedPubMedCentral

23.

S. Bossoni, L. Chiesa, A. Giustina, Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection. Endocrine 68(2), 253–254 (2020). https://doi.org/10.1007/s12020-020-02326-0CrossRefPubMedPubMedCentral

24.

M. Dianatfar, M. Sanjari, B. Dalfardi, Hypoparathyroidism after COVID-19 Pneumonia. Shiraz E-Med J. 22, e115832 (2021)

25.

J.B. Bonnet, E. Berchoux, A. Sultan, Decompensated primary hypoparathyroidism in a patient with COVID-19. Ann. Endocrinol. 82(2), 123–124 (2021). https://doi.org/10.1016/j.ando.2021.02.002CrossRef

26.

B. Pla, M. Silva, A. Arranz, M. Marazuela, Hipocalcemia severa y resistente al tratamiento en paciente con neumonía bilateral COVID-19 [Severe and treatment-resistant hypocalcemia in patient with bilateral COVID-19 pneumonia]. Endocrinol. Diabetes Nutr. 68(7), 518–519 (2021). https://doi.org/10.1016/j.endinu.2020.06.002

27.

V.E. Georgakopoulou, P. Avramopoulos, P. Papalexis, A. Bitsani, C. Damaskos, A. Garmpi et al. COVID-19 induced hypoparathyroidism: A case report. Exp. Ther. Med 23(5), 346 (2022). https://doi.org/10.3892/etm.2022.11276CrossRefPubMedPubMedCentral

28.

D. Grigoravičius, L. Šiaulienė, Ž. Visockienė, Unrecognized Primary Hypoparathyroidism with Severe Hypocalcemia in the Presence of COVID-19 Infection. Acta Med Litu. 29(1), 136–143 (2022). https://doi.org/10.15388/Amed.2021.29.1.9CrossRefPubMedPubMedCentral

29.

L. Di Filippo, A.M. Formenti, P. Rovere-Querini, M. Carlucci, C. Conte, F. Ciceri et al. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine 68(3), 475–478 (2020). https://doi.org/10.1007/s12020-020-02383-5CrossRefPubMedPubMedCentral

30.

L. Di Filippo, A.M. Formenti, M. Doga, S. Frara, P. Rovere-Querini, E. Bosi, Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients. Endocrine 71(1), 9–13 (2021)CrossRefPubMed

31.

L. Di Filippo, A.M. Formenti, M. Doga, E. Pedone, P. Rovere-Querini, A. Giustina, Radiological Thoracic Vertebral Fractures are Highly Prevalent in COVID-19 and Predict Disease Outcomes. J. Clin. Endocrinol. Metab. 106(2), e602–e614 (2021). https://doi.org/10.1210/clinem/dgaa738CrossRefPubMed

32.

A. Raesi, E. Saedi Dezaki, H. Moosapour, F. Saeidifard, Z. Habibi, F. Rahmani et al. Hypocalcemia in Covid-19: A Prognostic Marker for Severe Disease. Iran. J. Pathol. 16(2), 144–153 (2021). https://doi.org/10.30699/IJP.2020.130491.2442CrossRefPubMed

33.

E. Puca, E. Puca, P. Pipero, H. Kraja, N. Como, Severe hypocalcaemia in a COVID-19 female patient. Endocrinol. Diabetes Metab. Case Rep. 2021, 20–0097 (2021). https://doi.org/10.1530/EDM-20-0097CrossRefPubMedPubMedCentral

34.

A. Abobaker, A. Alzwi, The effect of COVID-19 on parathyroid glands. J. Infect. Public Health 14(6), 724–725 (2021). https://doi.org/10.1016/j.jiph.2021.04.002CrossRefPubMedPubMedCentral

35.

Y. Ding, L. He, Q. Zhang, Z. Huang, X. Che, J. Hou et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J. Pathol. 203(2), 622–630 (2004). https://doi.org/10.1002/path.1560CrossRefPubMedPubMedCentral

36.

A.K. Murugan, A.S. Alzahrani, SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases. J. Inflamm. Res 14, 6191–6221 (2021). https://doi.org/10.2147/JIR.S332705CrossRefPubMedPubMedCentral

37.

R. Krapf, P. Jaeger, H.N. Hulter, Chronic respiratory alkalosis induces renal PTH-resistance, hyperphosphatemia and hypocalcemia in humans. Kidney Int 42(3), 727–734 (1992). https://doi.org/10.1038/ki.1992.340CrossRefPubMed

38.

G. Alfano, F. Fontana, G. Mori, F. Giaroni, A. Ferrari, S. Giovanella et al. Modena Covid-19 Working Group (MoCo19). Acid base disorders in patients with COVID-19. Int Urol. Nephrol. 54(2), 405–410 (2022). https://doi.org/10.1007/s11255-021-02855-1CrossRefPubMed

39.

A.K. Murugan, A.S. Alzahrani, SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves’ disease. Endocrine 73(2), 243–254 (2021). https://doi.org/10.1007/s12020-021-02770-6CrossRefPubMedPubMedCentral

40.

S. Fabbri, R. Zonefrati, G. Galli, G. Gronchi, G. Perigli, A. Borrelli, M.L. Brandi, In Vitro Control of Genes Critical for Parathyroid Embryogenesis by Extracellular Calcium. J. Endocr. Soc. 4(7), bvaa058 (2020). https://doi.org/10.1210/jendso/bvaa058CrossRefPubMedPubMedCentral

41.

B.L. Jones, S.M. Smith, Calcium-Sensing Receptor: A Key Target for Extracellular Calcium Signaling in Neurons. Front Physiol. 7, 116 (2016). https://doi.org/10.3389/fphys.2016.00116CrossRefPubMedPubMedCentral

42.

V.N. Shah, B. Chagot, W.J. Chazin, Calcium-Dependent Regulation of Ion Channels. Calcium Bind Proteins 1(4), 203–212 (2006)PubMedPubMedCentral

43.

H.A. Lysbeth, W.H. Quenton, M.I. Callum, R. Kiefer, O. Nikitas, S. Eoin, et al.: The SARS-CoV-2 envelope (E) protein forms a calcium- and voltage-activated calcium channel. https://doi.org/10.1101/2022.10.11.511775.

44.

R. Minakshi, K. Padhan, S. Rehman, M.I. Hassan, F. Ahmad, The SARS coronavirus 3a protein binds calcium in its cytoplasmic domain. Virus Res. 191, 180–183 (2014). https://doi.org/10.1016/j.virusres.2014.08.001CrossRefPubMed

45.

M.-S. João, H.S. Noah, K.W. Harrison, J.M. Matthew, S.M. Venkata, J.D. Aurelio et al. pH- and Calcium-Dependent Aromatic Network in the SARS-CoV-2 Envelope Protein. J. Am. Chem. Soc. 144(15), 6839–6850 (2022). https://doi.org/10.1021/jacs.2c00973CrossRef

46.

G. Khelashvili, A. Plante, M. Doktorova, H. Weinstein, Ca2+-dependent mechanism of membrane insertion and destabilization by the SARS-CoV-2 fusion peptide. Biophys. J. 120(6), 1105–1119 (2021). https://doi.org/10.1016/j.bpj.2021.02.023CrossRefPubMedPubMedCentral

47.

P. Singh, S. Mukherji, S. Basak, M. Hoffmann, D.K. Das, Dynamic Ca2+ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. Cell Rep. 39(3), 110694 (2022). https://doi.org/10.1016/j.celrep.2022.110694CrossRefPubMedPubMedCentral

48.

Y. Zhou, T.K. Frey, J.J. Yang, Viral calciomics: interplays between Ca2+ and virus. Cell Calcium 46(1), 1–17 (2009). https://doi.org/10.1016/j.ceca.2009.05.005CrossRefPubMedPubMedCentral

49.

Z.M. Liu, J.P. Li, S.P. Wang, D.Y. Chen, W. Zeng, S.C. Chen et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. Int J. Med Sci. 17(16), 2468–2476 (2020). https://doi.org/10.7150/ijms.48396CrossRefPubMedPubMedCentral

50.

L. Iamartino, M.L. Brandi, The calcium-sensing receptor in inflammation: Recent updates. Front Physiol. 13, 1059369 (2022). https://doi.org/10.3389/fphys.2022.1059369CrossRefPubMedPubMedCentral

51.

B. Torres, P. Alcubilla, A. González-Cordón, A. Inciarte, M. Chumbita, C. Cardozo et al. COVID19 Hospital Clínic Infectious Diseases Research Group. Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome. Int J. Infect. Dis. 104, 164–168 (2021). https://doi.org/10.1016/j.ijid.2020.11.207CrossRefPubMed

52.

S. Bennouar, A.B. Cherif, A. Kessira, D.E. Bennouar, S. Abdi, Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19. J. Am. Coll. Nutr. 40(2), 104–110 (2021). https://doi.org/10.1080/07315724.2020.1856013CrossRefPubMed

53.

C. Yang, X. Ma, J. Wu, J. Han, Z. Zheng, H. Duan et al. Low serum calcium and phosphorus and their clinical performance in detecting COVID-19 patients. J. Med Virol. 93(3), 1639–1651 (2021). https://doi.org/10.1002/jmv.26515CrossRefPubMed

54.

S. Hashemipour, S. Kiani, P. Shahsavari, S. Afshar, A. Ghobadi, S.M.R.H. Khairkhahan et al. Hypocalcemia in hospitalized patients with COVID-19: roles of hypovitaminosis D and functional hypoparathyroidism. J. Bone Min. Metab. 40(4), 663–669 (2022). https://doi.org/10.1007/s00774-022-01330-wCrossRef

55.

J. Liu, P. Han, J. Wu, J. Gong, D. Tian, Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J. Infect. Public Health 13(9), 1224–1228 (2020). https://doi.org/10.1016/j.jiph.2020.05.029CrossRefPubMedPubMedCentral

56.

J.K. Sun, W.H. Zhang, L. Zou, Y. Liu, J.J. Li, X.H. Kan et al. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging 12(12), 11287–11295 (2020). https://doi.org/10.18632/aging.103526CrossRefPubMedPubMedCentral

57.

A. Pizzini, M. Aichner, S. Sahanic, A. Böhm, A. Egger, G. Hoermann et al. Impact of Vitamin D Deficiency on COVID-19-A Prospective Analysis from the CovILD Registry. Nutrients 12(9), 2775 (2020). https://doi.org/10.3390/nu12092775CrossRefPubMedPubMedCentral

58.

J.P. Bilezikian, A.A. Khan, J.T. Potts Jr., Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 335–339 (2009). https://doi.org/10.1210/jc.2008-1763CrossRefPubMedPubMedCentral

59.

J.P. Bilezikian, A. Khan, J.T. Potts Jr, M.L. Brandi, B.L. Clarke, D. Shoback et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Min. Res 26(10), 2317–2337 (2011). https://doi.org/10.1002/jbmr.483CrossRef

60.

B.L. Clarke, E.M. Brown, M.T. Collins, H. Jüppner, P. Lakatos, M.A. Levine et al. Epidemiology and Diagnosis of Hypoparathyroidism. J. Clin. Endocrinol. Metab. 101(6), 2284–2299 (2016). https://doi.org/10.1210/jc.2015-3908CrossRefPubMedPubMedCentral

61.

N. Siraj, Y. Hakami, A. Khan, Medical Hypoparathyroidism. Endocrinol. Metab. Clin. North Am. 47(4), 797–808 (2018). https://doi.org/10.1016/j.ecl.2018.07.006CrossRefPubMed

62.

J.P. Bilezikian, Hypoparathyroidism. J. Clin. Endocrinol. Metab. 105(6), 1722–1736 (2020). https://doi.org/10.1210/clinem/dgaa113CrossRefPubMedPubMedCentral

63.

D. Shoback, Clinical practice. Hypoparathyroidism. N. Engl. J. Med 359(4), 391–403 (2008). https://doi.org/10.1056/NEJMcp0803050CrossRefPubMed

64.

C.J. Goddard, A. Mbewu, J.M. Evanson, Symptomatic hypocalcaemia associated with metastatic invasion of the parathyroid glands. Br. J. Hosp. Med 43(1), 72 (1990)PubMed

65.

G. Mazziotti, E. Lavezzi, A. Brunetti, M. Mirani, G. Favacchio, A. Pizzocaro et al. Humanitas COVID19 Task Force. Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19. J. Endocrinol. Investig. 44(10), 2285–2293 (2021). https://doi.org/10.1007/s40618-021-01535-2CrossRef

66.

L. di Filippo, A. Allora, M. Locatelli, P. Rovere Querini, S. Frara, G. Banfi et al. Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response. Endocrine 74(2), 219–225 (2021). https://doi.org/10.1007/s12020-021-02882-zCrossRefPubMedPubMedCentral

67.

M.F. Siddiqui, N. Maalouf, Spontaneous Resolution of Primary Hyperparathyroidism Following COVID-19 Infection. J. Endocr. Soc. 5(Suppl_1), A223–A224 (2021). https://doi.org/10.1210/jendso/bvab048.454CrossRef

68.

T. Li, L. Wang, H. Wang, Y. Gao, X. Hu, X. Li et al. Characteristics of laboratory indexes in COVID-19 patients with non-severe symptoms in Hefei City, China: diagnostic value in organ injuries. Eur. J. Clin. Microbiol Infect. Dis. 39(12), 2447–2455 (2020). https://doi.org/10.1007/s10096-020-03967-9CrossRefPubMedPubMedCentral

69.

S. Battisti, N. Napoli, C. Pedone, M. Lombardi, G. Leanza, F. Tramontana et al. Vertebral fractures and mortality risk in hospitalised patients during the COVID-19 pandemic emergency. Endocrine 74(3), 461–469 (2021). https://doi.org/10.1007/s12020-021-02872-1CrossRefPubMedPubMedCentral

70.

M. Tahtabasi, N. Kilicaslan, Y. Akin, E. Karaman, M. Gezer, Y.K. Icen et al. The Prognostic Value of Vertebral Bone Density on Chest CT in Hospitalized COVID-19 Patients. J. Clin. Densitom. 24(4), 506–515 (2021). https://doi.org/10.1016/j.jocd.2021.07.007CrossRefPubMedPubMedCentral

71.

A. Giustina, R. Bouillon, N. Binkley, C. Sempos, R.A. Adler, J. Bollerslev et al. Controversies in Vitamin D: A Statement From the Third International Conference. JBMR 4(12), e10417 (2020). https://doi.org/10.1002/jbm4.10417CrossRef

72.

J.H. Krege, D. Kendler, K. Krohn, H. Genant, J. Alam, P.Y. Berclaz et al. Relationship Between Vertebral Fracture Burden, Height Loss, and Pulmonary Function in Postmenopausal Women With Osteoporosis. J. Clin. Densitom. 18(4), 506–511 (2015). https://doi.org/10.1016/j.jocd.2015.02.004CrossRefPubMed

73.

L. di Filippo, N. Compagnone, S. Frara, A. Allora, M. Doga, P. Rovere Querini et al. Vertebral fractures at hospitalization predict impaired respiratory function during follow-up of COVID-19 survivors. Endocrine 77(2), 392–400 (2022). https://doi.org/10.1007/s12020-022-03096-7CrossRefPubMed

74.

L. di Filippo, S. Frara, M. Doga, A. Giustina, The osteo-metabolic phenotype of COVID-19: an update. Endocrine 78(2), 247–254 (2022). https://doi.org/10.1007/s12020-022-03135-3CrossRefPubMedPubMedCentral

75.

N. Napoli, A.L. Elderkin, D.P. Kiel, S. Khosla, Managing fragility fractures during the COVID-19 pandemic. Nat. Rev. Endocrinol. 16(9), 467–468 (2020). https://doi.org/10.1038/s41574-020-0379-zCrossRefPubMedPubMedCentral

76.

H.E. Davis, L. McCorkell, J.M. Vogel, E.J. Topol, Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol 21(3), 133–146 (2023). https://doi.org/10.1038/s41579-022-00846-2CrossRefPubMedPubMedCentral

77.

N. Aojula, A. Ready, N. Gittoes, Z. Hassan-Smith, Management of Parathyroid Disease during the COVID-19 Pandemic. J. Clin. Med. 10(5), 920 (2021). https://doi.org/10.3390/jcm10050920CrossRefPubMedPubMedCentral

78.

E.M. Alfadhli, Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic. Clin. Ther. 43(4), 711–719 (2021). https://doi.org/10.1016/j.clinthera.2021.02.003CrossRefPubMedPubMedCentral

79.

F.L.M. Montenegro, M.D.G. Brescia, S.S. Arap, M.A.V. Kulcsar, M.R. Tavares, L.P. Kowalski, Parathyroid surgery during the COVID-19 pandemic: Time to think about the “New Normal”. Clinics 75, e2218 (2020). https://doi.org/10.6061/clinics/2020/e2218CrossRefPubMedPubMedCentral

80.

S. Nachimuthu, M.D. Assar, J.M. Schussler, Drug-induced QT interval prolongation: mechanisms and clinical management. Ther. Adv. Drug Saf. 3(5), 241–253 (2012). https://doi.org/10.1177/2042098612454283CrossRefPubMedPubMedCentral

81.

A.M. Uwitonze, M.S. Razzaque, Role of magnesium in vitamin D activation and function. J. Am. Osteopath Assoc. 118(3), 181–189 (2018). https://doi.org/10.7556/jaoa.2018.037CrossRefPubMed

Titel: Potential impacts of SARS-CoV-2 on parathyroid: current advances and trends
verfasst von: Avaniyapuram Kannan Murugan
Ali S. Alzahrani
Publikationsdatum: 16.06.2023
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2023
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03415-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Potential impacts of SARS-CoV-2 on parathyroid: current advances and trends

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Plasma-free metanephrines, nerve growth factor, and renalase significance in patients with PCOS

Prevalence and incidence of type 2 diabetes mellitus in patients with adrenal incidentalomas: a study of 709 cases

Parathyroid carcinoma: molecular therapeutic targets

Geographic variation in the association between Hashimoto’s thyroiditis and Papillary thyroid carcinoma, a meta-analysis

TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake

Function and form of the shoulder in congenital and untreated growth hormone deficiency

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin